Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD13-02 in r/r CD7+ Hematologic Malignancies
NCT05923541Phase 1Completed
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD13-02 in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by Henan Cancer Hospital. Primary endpoint: Overall Response Rate at 12 weeks. Started Jun 2023; status: completed.
02
Drugs
RD13-02
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT05923541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05923541.